As of June 30, 2023, Fuse Medical, Inc. carries a market capitalization of 4.51M, placing it among publicly traded companies globally. Its enterprise value stands at 6.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.51M |
| Enterprise Value | 6.48M |
As of June 30, 2023, Fuse Medical, Inc. has 73.90M shares outstanding.
| Shares Outstanding | 73.90M |
As of June 30, 2023, Fuse Medical, Inc. trades at a trailing price-to-earnings ratio of 1.20. The price-to-sales ratio is 0.24, and the price-to-book ratio stands at -19.46.
| PE Ratio | 1.20 |
| PS Ratio | 0.24 |
| PB Ratio | -19.46 |
| P/TBV Ratio | -1.35 |
| P/FCF Ratio | 239.35 |
| P/OCF Ratio | 233.04 |
These figures are as of June 30, 2023. The EV/Sales ratio of 0.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Fuse Medical, Inc. trades at an EV/FCF ratio of 28.14, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 6.48M versus a market cap of 4.51M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.35 |
| EV / FCF | 28.14 |
As of June 30, 2023, Fuse Medical, Inc. maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -958.83, indicating conservative leverage, while an interest coverage ratio of -0.49 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.06 |
| Quick Ratio | 0.31 |
| Debt / Equity | -958.83 |
| Debt / EBITDA | -21.16 |
| Interest Coverage | -0.49 |
These figures cover the twelve months ended June 30, 2023. Return on invested capital (ROIC) is negative at -408.46, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 18.91, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1,077.28, useful for judging operating efficiency across full business cycles. The company generates approximately 570,661.18 in revenue per employee across its workforce of 32.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.70 indicates how many times Fuse Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | 18.91 |
| Return on Invested Capital (ROIC) | -408.46 |
| Return on Capital Employed (ROCE) | 1,077.28 |
| Revenue Per Employee | 570,661.18 |
| Employee Count | 32.25 |
| Inventory Turnover | 0.70 |
Over the twelve months ended June 30, 2023, Fuse Medical, Inc. recorded 26,467.00 in income tax expense. That works out to an effective tax rate of 0.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.66M, leaving 3.63M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 26,467.00 |
| Effective Tax Rate | 0.72 |
As of the close on October 8, 2026, Fuse Medical, Inc.'s stock has declined approximately 55.36% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.10.
| 52-Week Price Change | -55.36% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.10 |
Over the twelve months ended June 30, 2023, Fuse Medical, Inc. generated 18.40M in revenue and converted that into 3.63M in net income, yielding earnings per share of 0.05. EBITDA reached -104,965.00, while operating income came in at -239,702.00.
| Revenue | 18.40M |
| Gross Profit | 11.95M |
| Operating Income | -239,702.00 |
| Pretax Income | 3.66M |
| Net Income | 3.63M |
| EBITDA | -104,965.00 |
| EBIT | -239,702.00 |
| Earnings Per Share (EPS) | 0.05 |
As of June 30, 2023, Fuse Medical, Inc. holds 253,378.00 in cash and equivalents against 2.22M in total debt, resulting in a net debt position of 1.97M. Total book value stands at -231,627.00, with working capital of 754,339.00 providing operational flexibility.
| Cash & Cash Equivalents | 253,378.00 |
| Total Debt | 2.22M |
| Net Debt | 1.97M |
| Equity (Book Value) | -231,627.00 |
| Working Capital | 754,339.00 |
Fuse Medical, Inc. produced 18,641.00 in operating cash flow over the twelve months ended June 30, 2023. After subtracting - - in capital expenditures, free cash flow totaled 18,641.00 - equivalent to 0.00 per share.
| Operating Cash Flow | 18,641.00 |
| Free Cash Flow | 18,641.00 |
Over the twelve months ended June 30, 2023, Fuse Medical, Inc. posted a gross margin of 64.95, reflecting its pricing power and cost economics. The operating margin of -1.30 and net profit margin of 19.72 provide insight into operational efficiency.
| Gross Margin | 64.95 |
| Operating Margin | -1.30 |
| Pretax Margin | 19.86 |
| Profit Margin | 19.72 |
| EBITDA Margin | -0.57 |
These figures cover the twelve months ended June 30, 2023. Free cash flow yield stands at 0.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.19, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fuse Medical, Inc. shareholders.
| Shareholder Yield | 8.19 |
| FCF Yield | 0.42 |
Fuse Medical, Inc.'s most recent stock split took place on June 13, 2014 with a 731:50 split ratio.
| Last Split Date | 6/13/2014 |
| Split Ratio | 731:50 |
As of June 30, 2023, Fuse Medical, Inc. has an Altman Z-Score of 1.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.07 |